<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421392</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0346</org_study_id>
    <nct_id>NCT03421392</nct_id>
  </id_info>
  <brief_title>Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT</brief_title>
  <acronym>SYMPATHIC</acronym>
  <official_title>Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of Immunologic and Constitutive Thrombocytopenia: Diagnostic and Prognostic Interest.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic thrombocytopenic purpura (ITP) is the most frequent auto-immune cytopenia. There
      is no specific biological marker and the diagnosis often results from the exclusion of other
      differential diagnoses, notably inherited thrombocytopenia.

      Recent studies have reported an original platelet destruction mechanism in ITP, by
      antibody-mediated desialylation of membrane proteins. The detection of platelet sialylation
      can be readily achieved using flow cytometry. This could provide a new biomarker of ITP,
      useful to ascertain a diagnosis of ITP and guide towards proper patient management.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the difference of sialylation between ITP patients and other causes of thrombocytopenia / controls</measure>
    <time_frame>18 months</time_frame>
    <description>a significant decrease in platelets sialylation in ITP patients, measured in flow cytometry with fluorescent Ricinus communis agglutinin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic value and therapy</measure>
    <time_frame>18 months</time_frame>
    <description>prognostic value of the level of sialylation in ITP patients regarding disease evolution and response of first line treatments and splenectomy.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Idiopathic thrombocytopenic purpura</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non immunological thrombocytopenia</arm_group_label>
    <description>patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without thrombocytopenia</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non interventional study</intervention_name>
    <description>non interventional study</description>
    <arm_group_label>Idiopathic thrombocytopenic purpura</arm_group_label>
    <arm_group_label>non immunological thrombocytopenia</arm_group_label>
    <arm_group_label>without thrombocytopenia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        3 Populations will be recruited in the study:

        Number of topics planned:

        50 Patients in the PTI group 50 patients in the non-immunological thrombocytopenia group 50
        patients in the control group
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18yo) with a diagnosis of ITP (primary acute, persisting or
             chronical)

          -  Adult patients (&gt;18yo) with a diagnosis of non immunological thrombocytopenia
             (constitutive thrombocytopenia, myelodysplastic syndrome, chemotherapy-induced
             thrombocytopenia)

          -  Adult patients (&gt;18 yo) without thrombocytopenia

          -  Enrolled in a Social Security system

          -  Having provided informed consent

        Exclusion Criteria:

          -  Minor patients (&lt;18 yo)

          -  Enrolled in another clinical study

          -  Having received corticosteroids or polyvalent immunoglobulins in the past 4

          -  weeks or anti-platelet therapy or NSAID during the past 7 days

          -  Having received platelet transfusion in the past fortnight

          -  With proven iron deficiency

          -  With drug-induced immune-allergic thrombocytopenia.

          -  Pregnant and breastfeeding women,

          -  guardian patients, will be excluded from this population.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Fouassier, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Fouassier, Dr</last_name>
    <phone>02 40 08 40 49</phone>
    <email>marc.fouassier@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Fouassier, Dr</last_name>
      <phone>02 40 08 40 49</phone>
      <email>marc.fouassier@chu-nantes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky R, Ruan M, Zhu L, Zeng Q, Tao L, Zhai ZM, Peng J, Hou M, Leytin V, Freedman J, Hoffmeister KM, Ni H. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015 Jul 17;6:7737. doi: 10.1038/ncomms8737.</citation>
    <PMID>26185093</PMID>
  </reference>
  <reference>
    <citation>SÃ¸rensen AL, Rumjantseva V, Nayeb-Hashemi S, Clausen H, Hartwig JH, Wandall HH, Hoffmeister KM. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood. 2009 Aug 20;114(8):1645-54. doi: 10.1182/blood-2009-01-199414. Epub 2009 Jun 11.</citation>
    <PMID>19520807</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>constitutive thrombocytopenia</keyword>
  <keyword>central thrombocytopenia</keyword>
  <keyword>platelets</keyword>
  <keyword>sialylation</keyword>
  <keyword>flow cytometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

